Mitofusin-2 ameliorates high-fat diet-induced insulin resistance in liver of rats

World Journal of Gastroenterology

Volumn 19, Issue 10, 2013, Pages 1572-1581

  Gan, Ke Xin ^a   Wang, Chao ^b   Chen, Jin Hu ^b   Zhu, Chun Jing ^a   Song, Guang Yao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

High fat diet; Insulin pathway; Insulin resistance; Liver; Mitofusin 2

Indexed keywords

CHOLESTEROL; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MITOFUSIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B BETA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84875298685     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i10.1572     Document Type: Article

References (38)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428 [PMID: 15836891 DOI: 10.1016/S0140-6736(05)66378-7]
2. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997; 50: 191-197 [PMID: 9175399 DOI: 10.1016/S0300-2977(97)00012-0]
3. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998; 182: 3-11 [PMID: 9609109 DOI: 10.1210/er.16.2.117]
4. Kerouz NJ, Hörsch D, Pons S, Kahn CR. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 1997; 100: 3164-3172 [PMID: 9399964 DOI: 10.1172/ JCI119872]
5. Torisu T, Sato N, Yoshiga D, Kobayashi T, Yoshioka T, Mori H, Iida M, Yoshimura A. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 2007; 12: 143-154 [PMID: 17295835 DOI: 10.1111/j.1365-2443.2007.01044.x]
6. Liesa M, Palacín M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev 2009; 89: 799-845 [PMID: 19584314 DOI: 10.1152/physrev.00030.2008]
7. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401-414 [PMID: 18309108 DOI: 10.1161/CIRCRESAHA.107.165472]
8. Zorzano A, Liesa M, Palacín M. Mitochondrial dynamics as a bridge between mitochondrial dysfunction and insulin resistance. Arch Physiol Biochem 2009; 115: 1-12 [PMID: 19267277 DOI: 10.1080/13813450802676335]
9. Westermann B. Molecular machinery of mitochondrial fusion and fission. J Biol Chem 2008; 283: 13501-13505 [PMID: 18372247 DOI: 10.1074/jbc.R800011200]
10. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, Mc- Caffery JM, Chan DC. Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 2010; 141: 280-289 [PMID: 20403324 DOI: 10.1016/j.cell.2010.02]
11. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. J Cell Sci 2001; 114: 867-874 [PMID: 11181170]
12. Hernández-Alvarez MI, Thabit H, Burns N, Shah S, Brema I, Hatunic M, Finucane F, Liesa M, Chiellini C, Naon D, Zorzano A, Nolan JJ. Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC- 1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care 2010; 33: 645-651 [PMID: 20032281 DOI: 10.2337/dc09-1305]
13. Zorzano A, Liesa M, Palacín M. Role of mitochondrial dynamics proteins in the pathophysiology of obesity and type 2 diabetes. Int J Biochem Cell Biol 2009; 41: 1846-1854 [PMID: 19703653 DOI: 10.1016/j.biocel.2009.02.004]
14. Zorzano A, Hernández-Alvarez MI, Palacín M, Mingrone G. Alterations in the mitochondrial regulatory pathways constituted by the nuclear co-factors PGC-1alpha or PGC- 1beta and mitofusin 2 in skeletal muscle in type 2 diabetes. Biochim Biophys Acta 2010; 1797: 1028-1033 [PMID: 20175989 DOI: 10.1016/j.bbabio.2010.02.017]
15. Qu DM, Song GY, Gao Y, Wang J, Hu SG, Han M. Expression pattern of PGC-1α and Mfn2 in insulin resistance state and after recovery in rat. Jichu Yixue Yu Linchuang 2008; 28: 133-137
16. Gastaldi G, Russell A, Golay A, Giacobino JP, Habicht F, Barthassat V, Muzzin P, Bobbioni-Harsch E. Upregulation of peroxisome proliferator-activated receptor gamma coactivator gene (PGC1A) during weight loss is related to insulin sensitivity but not to energy expenditure. Diabetologia 2007; 50: 2348-2355 [PMID: 17828388 DOI: 10.1007/s00125- 007-0782-1]
17. Sebastián D, Hernández-Alvarez MI, Segalés J, Sorianello E, Muñoz JP, Sala D, Waget A, Liesa M, Paz JC, Gopalacharyulu P, Orešič M, Pich S, Burcelin R, Palacín M, Zorzano A. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. Proc Natl Acad Sci USA 2012; 109: 5523-5528 [PMID: 22427360 DOI: 10.1073/pnas. 1108220109]
18. Zhang R, Han M, Zheng B, Li YJ, Shu YN, Wen JK. Krüppellike factor 4 interacts with p300 to activate mitofusin 2 gene expression induced by all-trans retinoic acid in VSMCs. Acta Pharmacol Sin 2010; 31: 1293-1302 [PMID: 20711222 DOI: 10. 1038/aps.2010.96]
19. Meirelles K, Ahmed T, Culnan DM, Lynch CJ, Lang CH, Cooney RN. Mechanisms of glucose homeostasis after Rouxen- Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg 2009; 249: 277-285 [PMID: 19212182 DOI: 10.1097/SLA.0b013e3181904af0]
20. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10 [PMID: 8971073 DOI: 10.2337/diabetes.46.1.3]
21. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806 [PMID: 11742412 DOI: 10.1038/414799a]
22. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2005; 280: 26185-26192 [PMID: 15899901 DOI: 10.1074/jbc. M503062200]
23. Honda S, Aihara T, Hontani M, Okubo K, Hirose S. Mutational analysis of action of mitochondrial fusion factor mitofusin- 2. J Cell Sci 2005; 118: 3153-3161 [PMID: 15985463 DOI: 10.1242/jcs.02449]
24. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz- Schughart LA, Schölmerich J, Bollheimer LC. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 2006; 36: 485-501 [PMID: 16720718 DOI: 10.1677/jme.1.01909]
25. Gauthier MS, Couturier K, Charbonneau A, Lavoie JM. Effects of introducing physical training in the course of a 16-week high-fat diet regimen on hepatic steatosis, adipose tissue fat accumulation, and plasma lipid profile. Int J Obes Relat Metab Disord 2004; 28: 1064-1071 [PMID: 15254487 DOI: 10.1038/sj.ijo.0802628]
26. da Silva AA, Kuo JJ, Tallam LS, Hall JE. Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension. Hypertension 2004; 43: 383-387 [PMID: 14707164 DOI: 10.1161/01.HYP.0000111139.94378.74]
27. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003; 160: 189-200 [PMID: 12527753 DOI: 10.1083/jcb.200211046]
28. Chen X, Xu Y. Liver-specific reduction of Mfn2 protein by RNAi results in impaired glycometabolism and lipid homeostasis in BALB/c mice. J Huazhong Univ Sci Technolog Med Sci 2009; 29: 689-696 [PMID: 20037808 DOI: 10.1007/ s11596-009-0603-5]
29. Coletta DK, Mandarino LJ. Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. Am J Physiol Endocrinol Metab 2011; 301: E749-E755 [PMID: 21862724 DOI: 10.1152/ ajpendo.00363.2011]
30. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001; 15: 2099-2111 [PMID: 11641236 DOI: 10.1096/fj.01-0009rev]
31. Previs SF, Withers DJ, Ren JM, White MF, Shulman GI. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 2000; 275: 38990-38994 [PMID: 10995761 DOI: 10.1074/jbc. M006490200]
32. Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab 2009; 296: E985-E992 [PMID: 19223655 DOI: 10.1152/ajpendo.00004.2009]
33. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004; 101: 10422-10427 [PMID: 15240880 DOI: 10.1073/pnas.0402511101]
34. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42394-42398 [PMID: 12228220 DOI: 10.1074/jbc.C200444200]
35. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000; 275: 15985-15991 [PMID: 10821852 DOI: 10.1074/jbc.275.21.15985]
36. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47944-47949 [PMID: 11604392 DOI: 10.1074/jbc.M104602200]
37. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508 [PMID: 15509521 DOI: 10.1016/S0002-9440(10)63408-6]
38. Calegari VC, Alves M, Picardi PK, Inoue RY, Franchini KG, Saad MJ, Velloso LA. Suppressor of cytokine signaling-3 Provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 2005; 146: 579-588 [PMID: 15514089 DOI: 10.1210/en.2004-0466]